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Abstract
A 40-year-old woman was admitted for 6 months of progressive gait disturbance, lower
limb–predominant weakness, stiﬀness, falls, jaw dystonia, horizontal diplopia, and weight loss.
Neurologic examination revealed horizontal gaze paresis, limited jaw opening with palpable
masseter hypertrophy, and spastic paraparesis with sustained clonus and upgoing plantar responses. MRI revealed T2-hyperintense signal abnormalities in the dorsal pons, medulla, and
upper cervical cord central gray matter extending to C3, without gadolinium enhancement.
CSF showed mildly elevated protein and immunoglobulin (IgG) index with CSF-speciﬁc
oligoclonal bands. Neural autoantibody testing was positive for anti-Ri in CSF and serum by
mouse brain indirect immunoﬂuorescence and immunoblot. Testing for aquaporin-4 (AQP4)IgG and myelin oligodendrocyte glycoprotein (MOG)-IgG by cell-based assay was negative.
The patient received methylprednisolone 1 g for 5 days and IV immunoglobulin 2 g/kg over 2
days with prednisone taper and botulinum toxin injections for jaw dystonia. PET-CT revealed
an enlarged left axillary lymph node with high FDG uptake. Left axillary lymph node biopsy
conﬁrmed high-grade, locally invasive breast adenocarcinoma. Neurologic stabilization was
documented at 2-week follow-up after hospital discharge before modiﬁed radical mastectomy.
Our case demonstrates a clinical triad highly suggestive of anti–Ri-associated paraneoplastic
neurologic syndrome (Ri-PNS): gait instability, jaw dystonia, and horizontal gaze paresis. The
more slowly progressive course and poor response to immunotherapy help distinguish it from
AQP4-IgG–seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG-IgG–
associated disease (MOGAD) that share similar radiographic features. Early diagnosis, prompt
immunotherapy, and cancer treatment are paramount for disease stabilization.
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Pearls
c

c

The triad of progressive gait instability, jaw dystonia, and
horizontal diplopia is highly suggestive of Ri autoimmunity and coexisting breast or lung cancer.
Neurologic symptoms often antedate cancer diagnosis or
suggest recurrence.

Oy-sters
c

c

Despite overlapping radiologic features, symptom progression over weeks to months favors Ri-PNS over
NMOSD and MOGAD where nadir is typically less than
21 days.
Malnourishment related to jaw dystonia and paroxysmal
laryngospasm can contribute to morbidity and mortality.

Case Report
A 40-year-old woman presented with a 6-month history of
progressive gait disturbance, lower limb–predominant weakness, stiﬀness, falls, jaw dystonia, and horizontal diplopia. She
initially developed subtle gait instability that progressed to
stiﬀness in her legs and falls. Within 2 months, she started
using a cane and by 3 months developed more gait diﬃculty,
lower limb weakness, and cramping and required bilateral
assistance to ambulate. She endorsed insomnia sleeping only a
few consecutive hours each night.
She developed jaw opening diﬃculty that progressed over 2
months until she could only use a straw for nourishment and lost
20 kg. Two weeks later, she developed blurry vision that became
binocular horizontal diplopia. She was admitted for workup.
Neurologic examination revealed tachycardia up to 135, left
eye esotropia, near-absent bilateral horizontal saccades and
smooth pursuit, preserved convergence, limited jaw opening
with palpable masseter hypertrophy, and lower limb–
predominant weakness and spasticity. She had trace 5−/5
shoulder abduction and 4+/5 elbow extension weakness in
the upper extremities and 3/5 right hip ﬂexion, 4−/5 left hip
ﬂexion, 4−/5 right knee ﬂexion, 4+/5 left knee ﬂexion, 2/5
right dorsiﬂexion, and 4−/5 left dorsiﬂexion weakness in the
lower extremities. Spasticity was worse in the legs than arms.
Sensation was intact to pinprick, temperature, joint proprioception, and vibration. Deep tendon reﬂexes were diffusely hyperactive (3+ to 4+) with sustained ankle clonus and
bilateral Babinski signs. Finger-to-nose testing revealed a
subtle action tremor, and her gait was unsteady and spastic
requiring bilateral assistance.
MRI revealed high T2-weighted signal in the dorsal pons and
medulla (Figure 1 A.a, A.b) and upper cervical cord predominantly involving central gray matter (Figure 1 A.c, A.d),
without gadolinium enhancement. CSF showed inﬂammatory
changes including mildly elevated protein (487 mg/L), immunoglobulin (IgG) index (1.94), and CSF-speciﬁc
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oligoclonal bands, otherwise no pleocytosis (4 cells/μL) and
normal glucose (4.2 mmol/L).
Neural autoantibody testing was positive for anti-Ri in serum
by mouse brain indirect immunoﬂuorescence (IIF) and immunoblot (serum titer >1:7,680 by IIF). Positivity for anti-Ri
in CSF by IIF and immunoblot was also demonstrated (tested
at 1:2 using IIF; additional dilutions for CSF titer were not
performed because of limited sample volume). Testing for
aquaporin-4 (AQP4)-IgG and myelin oligodendrocyte glycoprotein (MOG)-IgG in serum by cell-based assay was
negative. Vitamin B1 (111 nmol/L), B6 (37 nmol/L), and
B12 (900 pmol/L) levels were normal. Additional laboratory
studies were negative for acid-fast bacilli, cryptococcus, herpes
simplex virus, varicella zoster virus, Treponema pallidum, and
Borrelia burgdoferi.
PET-CT revealed mass-like densities in the left breast without signiﬁcantly increased FDG uptake (maximum SUV 1.9)
most in keeping with benign ﬁbroadenomas, but also an enlarged left axillary lymph node with signiﬁcantly increased
FDG uptake (maximum SUV 6.0) suspicious for malignancy.
Left axillary lymph node histopathology conﬁrmed highgrade, locally invasive breast adenocarcinoma that was estrogen receptor positive, progesterone receptor weakly
positive, with HER2 gene ampliﬁcation by ﬂuorescence in situ
hybridization (FISH).
The patient received IV methylprednisolone 1 g for 5 days
and IV immunoglobulin 2 g/kg over 2 days, followed by oral
prednisone 60 mg with 5-mg taper every 2 weeks. She received botulinum toxin injections (20 units, masseter muscles; 10 units, lateral pterygoids) for jaw dystonia with
minimal improvement before discharge.
At the 2-week follow-up, despite subtle improvement in
horizontal gaze and lower limb strength, she required a walker
and demonstrated persistent horizontal gaze deﬁcits, jaw
dystonia, and had lost 5 additional kilograms. Two weeks
later, she had a left modiﬁed radical mastectomy, complicated
by hypercapnic hypoxic respiratory failure, requiring nasotracheal intubation on postoperative day 3 in the setting of
ineﬀective mucus clearance/atelectasis, left lower lobe pneumonia, and right lower lobe segmental pulmonary embolus,
treated with apixaban 5 mg twice a day, piperacillin/
tazobactam for 7 days, chest physiotherapy, and tracheostomy to secure a long-term airway. Possible paroxysmal laryngospasm cannot be ruled out. Repeat MRI demonstrated
improvement in T2-hyperintense signal abnormalities in the
brainstem (Figure 1 B.a, B.b) and upper cervical cord
(Figure 1 B.c, B.d), despite limited neurologic improvement.

Discussion
We highlight a triad of gait instability, horizontal diplopia, and
jaw dystonia that should prompt consideration of testing for
Neurology.org/N
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Figure 1 MRI Signal Abnormalities in the Brainstem and Upper Cervical Cord at Initial Presentation (A.a–A.d) and 1 Month
Later (B.a–B.d) Following Immunotherapy

T2-hyperintense signal (arrows) in the periependymal dorsal pons and medulla on sagittal (A.a) and axial (A.b) T2/fluid-attenuated inversion recovery (FLAIR)
and upper cervical spinal cord central gray matter at C2 (A.c) and C2-C3 (A.d) levels on axial T2-weighted imaging. One month later, T2-hyperintensities were
less conspicuous in the brainstem (B.a, B.b) and upper cervical cord at C2 (B.c) and C2-3 (B.d) levels. No enhancement after gadolinium administration on T1weighted imaging or restricted diffusion on diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) images observed (not shown).

antineuronal nuclear autoantibody type 2 (ANNA-2, also
termed anti-Ri). Most patients with anti–Ri-associated paraneoplastic neurologic syndrome (Ri-PNS) are women
(66%–78%) presenting with progressive brainstem, cerebellar, and/or spinal cord dysfunction, evolving over weeks to
months with an underlying breast or lung cancer found in the
large majority (>70%).1-3
Clinical manifestations result from CNS injury to neuroanatomic
regions expressing neuro-oncologic ventral antigen (NOVA)-1
and NOVA-2, which are RNA-binding proteins that regulate
neuronal pre-mRNA expressed in the brainstem and ventral
spinal cord.1,4 Paraneoplastic autoantibodies, ANNA-2/anti-Ri,
result from an immune-mediated response against processed
onconeural polypeptides presented to T helper cells on MHC
Class I. The pathogenesis is primarily driven by Ri-speciﬁc cytotoxic CD8+ T cells, which produce cytotoxic factors (e.g.,
perforin and granzymes), targeting tumor and neurons expressing
a common onconeural antigen.5 Response to immunotherapy in
Ri-PNS is often poor, although stabilization is possible with early
cancer-directed therapy and immunotherapy.5
In a retrospective case series of 28 patients with Ri autoimmunity, the most common initial symptom was gait instability
(86%).6 Horizontal gaze palsy (21%) and jaw dystonia (14%)
were also common accompaniments.6 These ﬁndings parallel
that of our patient who developed progressive gait disturbance, loss of conjugate horizontal eye movements, and
oromandibular dystonia over a span of 6 months. In a prospective clinical follow-up, among 6 patients with jaw dystonia, 5 had severely impaired nutrition and profound weight
loss.1 All 6 patients with jaw dystonia had horizontal gaze
paresis, suggesting that both these ﬁndings, when found
Neurology.org/N

together, may be a useful clinical clue for Ri-PNS. Likewise, in
a retrospective French cohort of 36 patients with anti-Ri, the
most common pattern at onset was a cerebellar syndrome
(39%) presenting with gait instability/ataxia and action
tremor, followed by subsequent brainstem involvement
causing oculomotor disturbances (17%) and oromandibular
or cervical dystonia (17%), similar to that in our patient.2
Dysautonomia (e.g., cardiac arrythmias), paroxysmal laryngospasm, and central hypoventilation during sleep (Ondine
syndrome) may occur in a minority of Ri-PNS cases but can
cause signiﬁcant harm when present, suggesting the need to
evaluate for these complications when suspected.2,7
In the French cohort, cancer was diagnosed in 33 patients
(92%).2 The neurologic syndrome antedated cancer diagnosis
in 24 patients (73%). Misdiagnosis occurred in 8 patients
(22%), mistaken for chronic neurodegenerative (e.g., atypical
parkinsonism) or neuroinﬂammatory (e.g., multiple sclerosis)
conditions of the CNS, during which time an underlying
cancer would go undetected.2 In our patient, early unprovoked falls, rigidity, ophthalmoparesis, and tremor could
have been mistaken for atypical parkinsonism.5,8 However,
progression over weeks to months would suggest the need to
investigate for alternative causes.
In terms of diﬀerential diagnosis, patients with autoantibodies
targeting Hu, Ma2/Ta, and neurochondrin may also present
with a progressive rhombencephalitis, with or without evidence
of broader neurologic dysfunction.3 AQP4-IgG–seropositive
neuromyelitis optica spectrum disorder (NMOSD) and MOGIgG–associated disorder (MOGAD) may present with encephalomyelitis and share certain radiographic features to
Ri-PNS yet can be distinguished by the temporal proﬁle and
Neurology | Volume 99, Number 1 | July 5, 2022
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Table 1 Comparison of Ri-PNS and Inflammatory CNS Demyelinating Disorders in Adults
Ri-PNS

AQP4-IgG NMOSD

MOGAD

Most common
neurologic
manifestations (in
decreasing frequency)

Cerebellar, brainstem, and spinal cord
syndromes presenting with gait
instability, ataxia, tremor, opsoclonus
myoclonus, oculomotor disturbances,
oromandibular or cervical dystonia with
or without laryngospasm, weight loss,
rarely (;5%) cardiac arrythmias, and
central hypoventilation during sleep
(Ondine syndrome)1,2,6

Single/recurrent longitudinally extensive
myelitis associated with painful tonic
spasms, unilateral/bilateral optic neuritis,
area postrema syndrome, brainstem
syndromes, diencephalic syndromes
(narcolepsy, hyponatremia, and
anorexia), and symptomatic
cerebral syndrome9,10

Recurrent bilateral (;50%), sequential
optic neuritis with optic disc edema (86%),
acute flaccid myelitis associated with
bowel/bladder and sexual dysfunction,
brainstem syndromes, acute
disseminated encephalomyelitis (ADEM),
and unilateral cortical FLAIRhyperintense Lesions in Anti-MOGassociated Encephalitis with Seizures
(FLAMES). Antecedent infectious or
inflammatory prodrome common9,10

Mode of onset

Progressive/insidious

Subacute (time to nadir 1–21 d)9

Subacute (time to nadir 1–21 d)9

Course

Progresses over weeks to months,
commonly in a gradual and less often
(30%) stepwise manner2

Relapsing; usually no progression
between relapses10

Monophasic or relapsing; usually no
progression between relapses10

Oncologic associations

High-risk autoantibody associated with
breast > lung cancer (>70%)3

Low risk (<5%)3

Low risk (5 case reports)3

CSF analysis

Pleocytosis (36%), elevated protein (68%), Variable. Usually, lymphocytic pleocytosis Usually, lymphocytic; oligoclonal bands in
and oligoclonal bands (80%) are
but can be neutrophilic or eosinophilic;
<10%9
common2
oligoclonal bands in <30%9

MRI findings

Mainly T2-weighted and FLAIR
hyperintensities with prominent
brainstem and upper cervical cord
involvement, rarely enhances2

T2-weighted and FLAIR hyperintensities
often enhancing. Predilection for
posterior optic nerve/chiasm;
longitudinally extensive (>3 vertebral
length, 85%) myelitis with prominent
swelling, central (gray and white matter)
involvement, ring-like or patchy
enhancement; and periependymal
lesions adjacent to lateral, third, or fourth
ventricles9,10

T2-weighted and FLAIR hyperintensities
with faint/no enhancement. Predilection
for anterior optic nerve; longitudinally
extensive (70%) myelitis with central gray
matter restriction (H-sign (30%) on axial
scans accompanied by a sagittal T2hyperintense line) and conus
involvement. Multifocal acute
disseminated encephalomyelitis (ADEMlike) large, fluffy white matter, deep gray
matter, and brainstem lesions; and
unilateral cortical FLAMES9

Treatment approaches

No consensus or randomized controlled
trial data, only expert opinion.
Cancer-directed treatment when cancer
detected, combined with
immunotherapies (e.g., IV
methylprednisolone 1 g for 3–5 d and
then weekly for 5–11 wk; prednisone
60 mg for 2–3 mo, followed by taper 10
mg/mo; IV immunoglobulin (IVIG) 0.4g/kg
for 5 d and then 1 dose weekly for 5–11
wk, plasma exchange 1–1.5 times plasma
volume for 5–7 sessions; rituximab 1 g
paired dose separated by 2 wk;
cyclophosphamide 0.6–1 g/m2 monthly
for 6 mo). Sometimes steroid-sparing
agents such as mycophenolate mofetil or
azathioprine are considered for
maintenance therapy5

Acute treatment: methylprednisolone 1 g
for 5 d, plasma exchange often required,
1–1.5 times plasma volume for 5–7
sessions
Maintenance: 3 FDA-approved
treatments available including
eculizumab (900 mg IV weekly for 4 doses
and then 1200 mg every 2 wk);
inebilizumab (300 mg IV on days 1 and 15,
every 6 mo); and satralizumab
(subcutaneous injections 125 mg weeks
0, 2, and 4 and then monthly). Other offlabel options include azathioprine,
mycophenolate mofetil, and rituximab

Lack of clinical trial evidence
Acute treatment:
Methylprednisolone 1 g for 5 d alone or in
combination with plasma exchange 1–1.5
times plasma volume for 5–7 sessions
Maintenance (when relapse): optimal
preventive therapy unknown, but options
include corticosteroids, azathioprine,
mycophenolate mofetil, rituximab, or
monthly IVIG

Treatment response

Poor outcomes, although exceptions
occur

Often incomplete

Typically good

response to immunotherapy. The neuroimaging appearance of
a lesion that involves the dorsal periependymal pons/medulla
and extends down into the cervical spinal cord with central
predilection may mimic AQP4-IgG NMOSD. Likewise,
brainstem and central gray matter–predominant spinal cord
involvement without enhancement on MRI may mimic
MOGAD, yet a relapse associated with these demyelinating
conditions would be expected to reach nadir of neurologic
dysfunction within days to weeks (i.e., less than 21 days).9 In
contrast, paraneoplastic neurologic disorders typically progress
34
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more slowly over weeks to months,9 often with a poor response
to immunotherapy.5 These disorders are summarized and
compared in Table 1.
The clinical spectrum and oncologic accompaniments of Ri
autoimmunity are being elucidated through detailed case reports and case series, but clinician recognition of this rare
disease may be lacking. We highlight a triad of symptoms
highly suggestive of Ri autoimmunity that should prompt
testing for this disease in the appropriate clinical context. This
Neurology.org/N
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may facilitate early diagnosis and management of neurologic
autoimmunity but also cancer-directed therapy. Although
evidence is limited, early immunotherapy and cancer treatment are likely paramount for preventing irreversible CNS
injury. Furthermore, early detection of known complications,
such as malnourishment from jaw dystonia and paroxysmal
laryngospasm, may help mitigate elements of preventable
morbidity and mortality associated with anti-Ri.
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